Structure and function of RGD peptides involved in bone biology

Cellular and Molecular Life Sciences

Volumn 60, Issue 1, 2003, Pages 119-132

  Schaffner, P ^a   Dard, M M ^a  

^a MERCK KGAA   (Germany)

Author keywords

Bone; Endothelium; Osteoblast; Osteoclast; RGD peptides

Indexed keywords

10,11 DIHYDRO 3 [3 (2 PYRIDINYLAMINO)PROPOXY] 5H DIBENZO[A,D]CYCLOHEPTENE 10 ACETIC ACID; ARGINYLGLYCYLASPARTIC ACID; CILENGITIDE; INTEGRIN; L 748415; SB 223245; SC 56631; SC 68448;

AMINO ACID SEQUENCE; BONE CELL; BONE REGENERATION; BONE STRUCTURE; DNA FLANKING REGION; DRUG ACTIVITY; ENDOTHELIUM CELL; HUMAN; HYDROPHOBICITY; MOLECULAR BIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PEPTIDE SYNTHESIS; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; ARGININE; ASPARTIC ACID; BONE AND BONES; ENDOTHELIUM, VASCULAR; HUMANS; INTEGRINS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; OLIGOPEPTIDES; OSTEOBLASTS; OSTEOCLASTS; PEPTIDES, CYCLIC; PROTEIN CONFORMATION; SUBSTRATE SPECIFICITY;

EID: 0037280017     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180300008     Document Type: Review

References (132)

1. Pierschbacher M. D. and Ruoslahti E. (1984) Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309: 30-33
2. Ruoslahti E. and Pierschbacher M. D. (1987) New perspectives in cell adhesion: RGD and integrins. Science 238: 491-497
3. Craig W. S., Cheng S., Mullen D. G., Blevitt J. and Pierschbacher, M. D. (1995) Concept and progress in the development of RGD-containing peptide pharmaceuticals. Biopolymers 37: 157-175
4. Duong L. T., Lakkakorpi P., Nakamura I. and Rodan G. A. (2000) Integrins and signalling in osteoclast function. Matrix Biol. 19: 97-105
5. Robey P. G., Fedarko N. S., Hefferan T. E., Bianco P., Vetter U. K., Grzesik W. et al. (1993) Structure and molecular regulation of bone matrix proteins. J. Bone Miner. Res. 8: 483-487
6. Gronthos S., Stewart K., Graves S. E., Hay S. and Simmons P. J. (1997) Integrin expression and function on human osteoblast-like cells. J. Bone Miner. Res. 12: 1189-1197
7. Robey P. G. (1996) Vertebrate mineralized matrix proteins: structure and function. Connect. Tissue Res. 35: 131-136
8. Blancher C., Omri B., Bidou L., Pessac B. and Crisanti P. (1996) Nectinepsin: a new extracellular matrix protein of the pexin family. Characterization of a novel cDNA encoding a protein with an RGD cell binding motif. J. Biol. Chem. 271: 26220-26226
9. Virji M. (1996) Adhesion receptors in microbial pathogenesis. Mol. Biol. Cell Adhesion Mol. 99-129
10. Goldman M. J. and Wilson J. M. (1995) Expression of alpha v beta 5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway. J. Virol. 69: 5951-5958
11. Humphries M. J. (1995) The LDV peptide motif: its role in integrin-ligand binding. Top. Mol. Med. 1: 27-35
12. Dechantsreiter M. A., Planker E., Matha B., Lohof E., Holzemann G., Jonczyk A. et al. (1999) N-Methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists. J. Med. Chem. 42: 3033-3040
13. Howe A., Aplin A. E., Alahari S. K. and Juliano R. L. (1998) Integrin signaling and cell growth control. Curr. Opin. Cell Biol. 10: 220-231
14. LeBaron R. G. and Athanasiou K. A. (2000) Extracellular matrix cell adhesion peptides: functional applications in orthopedic materials. Tissue Eng 6: 85-103
15. Rahman S., Aitken A., Flynn G., Formstone C. and Savidge G. F. (1998) Modulation of RGD sequence motifs regulates disintegrin recognition of alpha IIb beta 3 and alpha 5 beta 1 integrin complexes. Replacement of elegantin alanine-50 with proline, N-terminal to the RGD sequence, diminishes recognition of the alpha 5 beta 1 complex with restoration induced by Mn2+ cation. Biochem. J. 335: 57
16. Verrier S, Pallu S., Bareille R., Jonczyk A., Meyer J., Dard M. et al. (2002) Function of linear and cyclic RGD-containing peptides in osteoprogenitor cells adhesion process. Biomaterials 23: 585-596
17. Rezania A. and Healy K. E. (1999) Biomimetic peptide surfaces that regulate adhesion, spreading, cytoskeletal organization and mineralization of the matrix deposited by osteoblast-like cells. Biotechnol. Prog. 15: 19-32
18. Salter D. M., Robb J. E. and Wright M. O. (1997) Electrophysiological responses of human bone cells to mechanical stimulation: evidence for specific integrin function in mechanotransduction. J. Bone Miner. Res. 12: 1133-1141
19. Pakalns T., Haverstick K. L., Fields G. B., McCarthy J. B., Mooradian D. L. and Tirrell M. (1999) Cellular recognition of synthetic peptide amphiphiles in self-assembled monolayer films. Biomaterials 20: 2265-2279
20. Nicolaou K. C., Trujillo J. I., Jandeleit, B., Chibale K., Rosenfeld M., Diefenbach B. et al. (1998) Design, synthesis and biological evaluation of nonpeptide integrin antagonists. Bioorg. Med. Chem. 6: 1185-1208
21. Hern D. L. and Hubbell J. A. (1998) Incorporation of adhesion peptides into nonadhesive hydrogels useful for tissue resurfacing. J. Biomed. Mater. Res. 39: 266-276
22. Pierschbacher M. D. and Ruoslahti E. (1987) Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J. Biol. Chem. 262: 17294-17298
23. Kumagai H., Tajima M., Ueno Y., Giga-Hama Y. and Ohba M. (1991) Effect of cyclic RGD peptide on cell adhesion and tumor metastasis. Biochem. Biophys. Res. Commun. 177: 74-82
24. Cheng S., Craig W. S., Mullen D., Tschopp J. F., Dixon D. and Pierschbacher M. D. (1994) Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists. J. Med. Chem. 37: 1-8
25. Hirano Y., Kando Y., Hayashi T., Goto K. and Nakajima A. (1991) Synthesis and cell attachment activity of bioactive oligopeptides: RGD, RGDS, RGDV and RGDT. J. Biomed. Mater. Res. 25: 1523-1534
26. Healy K. E. (1999) Molecular engineering of materials for bioreactivity. Curr. Opin. Solid State Mat. Sci. 4: 381-387
27. Samanen J., Ali F., Bean J., Callahan J., Huffman W., Kopple K., Peishoff C. et al. (1994) Peptide mimetics as adhesion molecule antagonists. Cell. Adhes. 259-290
28. Mueller K., Obrecht D., Knierzinger A., Stankovic Ch., Spiegler C., Bannwarth W. et al. (1992) Building blocks for the induction or fixation of peptide conformations. In: Approaches in Lead Finding and Lead Optimization, pp. 513-531, Hoffmann-La Roche, Basel
29. Wermuth J., Goodman S. L., Jonczyk A. and Kessler H. (1997) Stereoismerism and biological activity of the selective and superactive αvβ3 integrin inhibitor cyclo(-RGDfV-) and its retro-inverso peptide. J. Am. Chem. Soc. 119: 1328-1335
30. Assa-Munt N., Jia X., Laakkonen P. and Ruoslahti E. (2001) Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 40: 2373-2378
31. Bogdanowich-Knipp S. J., Chakrabarti S., Williams T. D., Dillman R. K. and Siahaan T. J. (1999) Solution stability of linear vs. cyclic RGD peptides. J. Pept. Res. 53: 530-541
32. Geiger T. and Clarke S. (1987) Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J. Biol. Chem. 262: 785-794
33. Manning M. C., Patel K. and Borchardt R. T. (1989) Stability of protein pharmaceuticals. Pharm. Res. 6: 903-918
34. Bogdanowich-Knipp S. J., Jois D. S. and Siahaan T. J. (1999) The effect of conformation on the solution stability of linear vs. cyclic RGD peptides. J. Pept. Res. 53: 523-529
35. Gurrath M., Muller G., Kessler H., Aumailley M. and Timpl R. (1992) Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur. J. Biochem. 210: 911-921
36. Ivanov B., Grzesik W. and Robey F. A. (1995) Synthesis and use of a new bromoacetyl-derivatized heterotrifunctional amino acid for conjugation of cyclic RGD-containing peptides derived from human bone sialoprotein. Bioconjug. Chem. 6: 269-277
37. Xiao Y. and Truskey G. A. (1996) Effect of receptor-ligand affinity on the strength of endothelial cell adhesion. Biophys. J. 71: 2869-2884
38. Yamamoto M., Fisher J. E., Gentile M., Seedor J. G., Leu C. T., Rodan S. B. et al. (1998) The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology 139: 1411-1419
39. Mercer B., Markland F. and Minkin C. (1998) Contortrostatin, a homodimeric snake venom disintegrin, is a potent inhibitor of osteoclast attachment. J. Bone Miner. Res. 13: 409-414
40. Musial J., Niewiarowski S., Rucinski B., Stewart G. J., Cook J. J., Williams J. A. et al. (1990) Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins. RGD-containing peptides from viper venoms. Circulation 82: 261-273
41. Scarborough R. M., Rose J. W., Hsu M. A., Phillips D. R., Fried V. A., Campbell A. M. et al. (1991) Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J. Biol. Chem. 266: 9359-9362
42. Hoekstra W. J. and Poulter B. L. (1998) Combinatorial chemistry techniques applied to nonpeptide integrin antagonists. Curr. Med. Chem. 5: 195-204
43. Papadopoulos G. K., Ouzounis C. and Eliopoeulos E. (1998) RGD sequences in several receptor proteins: novel cell adhesion function of receptors? Int. J. Biol. Macormol. 22: 51-57
44. Ben-Ze'ev A., Farmer S. R. and Penman S. (1980) Protein synthesis requires cell-surface contact while nuclear events respond to cell shape in anchorage-dependent fibroblasts. Cell 21: 365-372
45. Mooney D., Hansen L., Vacanti J., Langer R., Farmer S. and Ingber D. (1992) Switching from differentiation to growth in hepatocytes: control by extracellular matrix. J. Cell Physiol 151: 497-505
46. Singhvi R., Kumar A., Lopez G. P., Stephanopoulos G. N., Wang D. I., Whitesides G. M. et al. (1994) Engineering cell shape and function. Science 264: 696-698
47. Ingber D. E., Prusty D., Sun Z., Betensky H. and Wang N. (1995) Cell shape, cytoskeletal mechanics and cell cycle control in angiogenesis. J. Biomech. 28: 1471-1484
48. Hynes R. O. (1992) Integrins: versatility, modulation and signaling in cell adhesion. Cell 69: 11-25
49. Dike L. E. and Ingber D. E. (1996) Integrin-dependent induction of early growth response genes in capillary endothelial cells. J. Cell Sci. 109: 63
50. Nicosia R. F. and Bonanno E. (1991) Inhibition of angiogenesis in vitro by Arg-Gly-Asp-containing synthetic peptide. Am. J. Patrol. 138: 829-833
51. Grant D. S., Tashiro K., Segui-Real B., Yamada Y., Martin G. R. and Kleinman H. K. (1989) Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58: 933-943
52. Ingber D. E. and Folkman J. (1989) Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix. J. Cell Biol. 109: 317-330
53. Albelda S. M., Daise M., Levine E. M. and Buck C. A. (1989) Identification and characterization of cell-substratum adhesion receptors on cultured human endothelial cells. J. Clin. Invest 83: 1992-2002
54. Cheng Y. F. and Kramer R. H. (1989) Human microvascular endothelial cells express integrin-related complexes that mediate adhesion to the extracellular matrix. J. Cell Physiol 139: 275-286
55. Conforti G., Zanetti A., Colella S., Abbadini M., Marchisio P. C., Pytela R. et al. (1989) Interaction of fibronectin with cultured human endothelial cells: characterization of the specific receptor. Blood 73: 1576-1585
56. Languino L. R., Gehlsen K. R., Wayner E., Carter W. G., Engvall E. and Ruoslahti E. (1989) Endothelial cells use alpha 2 beta 1 integrin as a laminin receptor. J. Cell Biol. 109: 2455-2462
57. Kirchhofer D., Languino L. R., Ruoslahti E. and Pierschbacher M. D. (1990) Alpha 2 beta 1 integrins from different cell types show different binding specificities. J. Biol. Chem. 265: 615-618
58. Kramer R. H., Cheng Y. F. and Clyman R. (1990) Human microvascular endothelial cells use beta 1 and beta 3 integrin receptor complexes to attach to laminin. J. Cell Biol. 111: 1233-1243
59. Massia S. P. and Hubbell J. A. (1992) Vascular endothelial cell adhesion and spreading promoted by the peptide REDV of the IIICS region of plasma fibronectin is mediated by integrin alpha 4 beta 1. J. Biol. Chem. 267: 14019-14026
60. Brooks P. C., Clark R. A. and Cheresh D. A. (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571
61. Bayless K. J., Salazar R. and Davis G. E. (2000) RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am. J. Pathol. 156: 1673-1683
62. Horton M. A. (1997) The alpha v beta 3 integrin 'vitronectin receptor'. Int. J. Biochem. Cell Biol. 29: 721-725
63. Horton, M. A. (1995) Interactions of connective tissue cells with the extracellular matrix. Bone 17: 51S-53S
64. Horton M. A., Nesbit M. A. and Helfrich M. H. (1995) Interaction of osteopontin with osteoclast integrins. Ann. N. Y. Acad. Sci. 760: 190-200
65. Heino J. (2000) The collagen receptor integrins have distinct ligand recognition and signalling functions. Matrix Biol. 19: 319-323
66. Staatz W. D., Walsh J. J., Pexton T. and Santoro S. A. (1990) The alpha 2 beta 1 integrin cell surface collagen receptor binds to the alpha 1 (I)-CB3 peptide of collagen. J. Biol. Chem. 265: 4778-4781
67. Rezania A. and Healy K. E. (1999) Integrin subunits responsible for adhesion of human osteoblast-like cells to biomimetic peptide surfaces. J. Orthop. Res. 17: 615-623
68. Rezania A., Thomas C. H., Branger A. B., Waters C. M. and Healy K. E. (1997) The detachment strength and morphology of bone cells contacting materials modified with a peptide sequence found within bone sialoprotein. J. Biomed. Mater. Res. 37: 9-19
69. Pistone M., Sanguineti C., Federici A., Sanguineti F., Defilippi P., Santolini F. et al. (1996) Integrin synthesis and utilization in cultured human osteoblasts. Cell Biol. Int. 20: 471-479
70. Grzesik W. J. and Robey P. G. (1994) Bone matrix RGD glycoproteins: immunolocalization and interaction with human primary osteoblastic bone cells in vitro. J. Bone Miner. Res. 9: 487-496
71. Healy K. E., Rezania A. and Stile R. A. (1999) Designing biomaterials to direct biological responses. Ann. N. Y. Acad. Sci. 87: 24-35
72. Ganss B., Kim R. H. and Sodek J. (1999) Bone sialoprotein. Crit Rev. Oral Biol. Med. 10: 79-98
73. Dee K. C., Andersen T. T. and Bizios R. (1998) Design and function of novel osteoblast-adhesive peptides for chemical modification of biomaterials. J. Biomed. Mater. Res. 40: 371-377
74. Hughes D. E., Salter D. M., Dedhar S. and Simpson R. (1993) Integrin expression in human bone. J. Bone Miner. Res. 8: 527-533
75. Rodan S. B. and Rodan G. A. (1997) Integrin function in osteoclasts. J. Endocrinol. 154 (Suppl.): S47-S56
76. Shankar G., Davison I., Helfrich M. H., Mason W. T. and Horton M. A. (1993) Integrin receptor-mediated mobilisation of intranuclear calcium in rat osteoclasts. J. Cell Sci. 105: 8
77. Paniccia R., Riccioni T., Zani B. M., Zigrino P., Scotlandi K. and Teti A. (1995) Calcitonin down-regulates immediate cell signals induced in human osteoclast-like cells by the bone sialoprotein-IIA fragment through a postintegrin receptor mechanism. Endocrinology 136: 1177-1186
78. Katayama Y., House C. M., Udagawa N., Kazama J. J., McFarland R. J., Martin T. J. et al. (1998) Casein kinase 2 phosphorylation of recombinant rat osteopontin enhances adhesion of osteoclasts but not osteoblasts. J. Cell Physiol 176: 179-187
79. Horton M. A., Dorey E. L., Nesbitt S. A., Samanen J., Ali F. E., Stadel J. M. et al. (1993) Modulation of vitronectin receptor-mediated osteoclast adhesion by Arg-Gly-Asp peptide analogs: a structure-function analysis. J. Bone Miner. Res. 8: 239-247
80. Sato M., Garsky V., Majeska R. J., Einhorn T. A., Murray J., Tashjian A. H. et al. (1994) Structure-activity studies of the s-echistatin inhibition of bone resorption. J. Bone Miner. Res. 9: 1441-1449
81. Sato M., Sardana M. K., Grasser W. A., Garsky V. M., Murray J. M. and Gould R. J. (1990) Echistatin is a potent inhibitor of bone resorption in culture. J. Cell Biol. 111: 1713-1723
82. Nakamura I., Tanaka H., Rodan G. A. and Duong L. T. (1998) Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells. Endocrinology 139: 5182-5193
83. Flores M. E., Norgard M., Heinegard D., Reinholt F. P. and Andersson G. (1992) RGD-directed attachment of isolated rat osteoclasts to osteopontin, bone sialoprotein, and fibronectin. Exp. Cell Res. 201: 526-530
84. Horton M. A., Taylor M. L., Arnett T. R. and Helfrich M. H. (1991) Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23 C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp. Cell Res. 195: 368-375
85. King K. L., D'Anza J. J., Bodary S., Pitti R., Siegel M., Lazarus R. A. et al. (1994) Effects of kistrin on bone resorption in vitro and serum calcium in vivo. J. Bone Miner. Res. 9: 381-387
86. Pluijm G. van der, Mouthaan H., Baas C., Groot H. de, Papapoulos S. and Lowik C. (1994) Integrins and osteoclastic resorption in three bone organ cultures: differential sensitivity to synthetic Arg-Gly-Asp peptides during osteoclast formation. J. Bone Miner. Res. 9: 1021-1028
87. Fisher J. E., Caulfield M. P., Sato M., Quartuccio H. A., Gould R. J., Garsky V. M. et al. (1993) Inhibition of osteoclastic bone resorption in vivo by echistatin, an 'arginyl-glycyl-aspartyl' (RGD)-containing protein. Endocrinology 132: 1411-1413
88. Wang Y., Goh S. Y. and Kuczera K. (1999) Molecular dynamics study of disulfide bond influence on properties of an RGD peptide. J. Pept. Res. 53: 188-200
89. Langer R., Cima L. G., Tamada J. A. and Wintermantel E. (1990) Future directions in biomaterials. Biomaterials 11: 738-745
90. Jeschke B, Meyer J., Jonczyk A., Kessler H., Adamietz P., Meenen N. H. et al. (2002) RGD-peptides for tissue engineering of articular artilage. Biomaterials 23: 3455-3463
91. Ruggeri Z. M., Houghten R. A., Russell S. R. and Zimmerman T. S. (1986) Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets. Proc. Natl. Acad. Sci. USA 83: 5708-5712
92. Nutt R. F. (1992) Design and synthesis of orally active fibrinogen receptor antagonists. Proceedings of the Second Japan Symposium on Peptide Chemistry, pp. 471-473, Protein Research Foundation, Osaka
93. Brooks P. C., Montgomery A. M., Rosenfeld M., Reisfeld R. A., Hu T., Klier G. et al. (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164
94. Westlin W. F. (2001) Integrins as targets of angiogenesis inhibiotion. Cancer 7: 139-143
95. Yan L., Moses M. A., Huang S. and Ingber D. E. (2000) Adhesion-dependent control of matrix metalloproteinase-2 activation in human capillary endothelial cells. J. Cell Sci. 113: 87
96. Mogford J. E., Davis G. E. and Meininger G. A. (1997) RGDN peptide interaction with endothelial alpha 5 beta 1 integrin causes sustained endothelin-dependent vasoconstriction of rat skeletal muscle arterioles. J. Clin. Invest 100: 1647-1653
97. Kirkpatrick C. J., Otto M., van Kooten T., Krump V., Kriegsmann J. and Bittinger F. (1999) Endothelial cell cultures as a tool in biomaterial research. Journal of Biomaterials Science: Materials in Medicine 10: 589-594
98. Kantlehner M., Finsinger D., Meyer J., Schaffner P., Jonczyk A., Diefenbach B. et al. (1999) Selective RGD-mediated adhesion of osteoblasts at surfaces of implants. Angew. Chem. Int. Ed. Engl. 38: 560-562
99. Healy K. E. and Ducheyne P. (1992) Hydration and preferential molecular adsorption on titanium in vitro. Biomaterials 13: 553-561
100. Sofia S., McCarthy M. B., Gronowicz G. and Kaplan D. L. (2001) Functionalized silk-based biomaterials for bone formation. J. Biomed. Mater. Res. 54: 139-148
101. Dettin M., Conconi M. T., Gambaretto R., Pasquato A., Marcella F., Di Bello C. et al. (2002) Novel osteoblast-adhesive peptides for dental/orthopedic biomaterials. J. Biomed. Mater. Res. 60: 466-471
102. Yang X. B., Roach H. I., Clarke N. M., Howdle S. M., Quirk R., Shakesheff K. M. et al. (2001) Human osteoprogenitor growth and differentiation on synthetic biodegradable structures after surface modification. Bone 29: 523-531
103. Eid K., Chen E., Griffith L. and Glowacki J. (2001) Effect of RGD coating on osteocompatibility of PLGA-polymer disks in a rat tibial wound. J. Biomed. Mater. Res. 57: 224-231
104. Schaffner P., Meyer J., Dard M., Wenz R. and Nies B. (1999) Induced tissue integration of bone implants by coating with bone selective RGD-peptides in vitro and in vivo studies. Journal of Materials Science: Materials in Medicine 10: 837-839
105. Yamamoto M., Gentile M., Seedor J. G., Balena R., Rodan S. B. and Rodan G. A. (1994) Echistatin prevents bone loss in ovariectomized mice. J. Bone Miner. Res. 9: 201
106. Engleman V. W., Nickols G. A., Ross F. P., Horton M. A., Griggs D. W., Settle S. L. et al. (1997) A peptidomimetic antagonist of the alpha v beta 3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J. Clin. Invest 99: 2284-2292
107. Gourvest J. F., Auberval M., Jouquey S., Stilz H. U., Wehner V., Sadick M. et al. (1996) Antiresorptive activity of a non-peptidic ligand of the αvβ3 vitronectin receptor. J. Bone Miner. Res. 11: 147
108. James I. E., Dodds R. A., Olivera D. L., Nuttall M. E. and Gowen M. (1996) Human osteoclastoma-derived stromal cells: correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo. J. Bone Miner. Res. 11: 1453-1460
109. Rodan S. B., Duong L, Fisher J. E., Gentil M., Leu C. T., Magy R. M. et al. (1996) A high affinity non-peptide αvβ3 ligand inhibits osteoclast activity in vitro and in vivo. J. Bone Miner. Res. 11: 289
110. Lark M. W., Stroup G. B., Hwang S. M., James I. E., Rieman D. J., Drake F. H. et al. (1999) Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis. J. Pharmacol. Exp. Ther. 291: 612-617
111. Rodan S. B., Duong L., Fisher J. E., Gentil M., Leu C. T., Nagy R. M. et al. (1996) A high affinity non-peptide αvβ3 ligand inhibits osteoclast activity in vitro and in vivo. ASBMR 18th Annual Meeting, vol. 11, suppl. 1, p. S 289, Blackwell Science, Cambridge, MA
112. Mitjans F., Meyer T., Fittschen C., Goodman S., Jonczyk A., Marshall J. F. et al. (2000) In vivo therapy of malignant melanoma by means of antagonists of alpha v integrins. Int. J. Cancer 87: 716-723
113. Carron C. P., Meyer D. M., Pegg J. A., Engleman V. W., Nickols M. A., Settle S. L. et al. (1998) A peptidomimetic antagonist of the integrin alpha v beta 3 inhibits leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res. 58: 1930-1935
114. Maeshima Y., Colorado P. C. and Kalluri R. (2000) Two RGD-independent alpha v beta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J. Biol. Chem. 275: 23745-23750
115. Schaffner P. (1997) Isolierung und Charakterisierung des alpha v beta 1 Integrins. Diploma Thesis, TH Darmstadt, Darmstadt
116. O'Regan A. and Berman J. S. (2000) Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. 81: 373-390
117. Shrimali R. K. and Reddy K. V. (2000) Integrins and disintegrins: the candidate molecular players in sperm-egg interaction. Indian J. Exp. Biol. 38: 415-424
118. Lin H. B., Sun W., Mosher D. F., Garcia-Echeverria C., Schaufelberger K., Lelkes P. I. et al. (1994) Synthesis, surface and cell-adhesion properties of polyurethanes containing covalently grafted RGD-peptides. J. Biomed. Mater. Res. 28: 329-342
119. Xia M., Sreedharan S. P., Bolin D. R., Gaufo G. O. and Goetzl E. J. (1997) Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J. Pharmacol. Exp. Ther. 281: 629-633
120. Sung V., Stubbs J. T., Fisher L., Aaron A. D. and Thompson E. W. (1998) Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha v beta 3 and alpha v beta 5 integrins. J. Cell Physiol 176: 482-494
121. Sasaguri K., Ganss B., Sodek J. and Chen J. K. (2000) Expression of bone sialoprotein in mineralized tissues of tooth and bone and in buccal-pouch carcinomas of Syrian golden hamsters. Arch. Oral Biol. 45: 551-562
122. Kumar R., Beguin S. and Hemker H. C. (1994) The influence of fibrinogen and fibrin on thrombin generation - evidence for feedback activation of the clotting system by clot bound thrombin. Thromb. Haemost. 72: 713-721
123. Mould A. P., Burrows L. and Humphries M. J. (1998) Identification of amino acid residues that form part of the ligand-binding pocket of integrin alpha 5 beta1. J. Biol. Chem. 273: 25664-25672
124. Scarborough R. M., Naughton M. A., Teng W., Rose J. W., Phillips D. R., Nannizzi L. et al. (1993) Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J. Biol. Chem. 268: 1066-1073
125. Dresner-Pollak R. and Rosenblatt M. (1994) Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis. J. Cell Biochem. 56: 323-330
126. Kostenuik P. J., Sanchez-Sweatman O., Orr F. W. and Singh G. (1996) Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. Clin. Exp. Metastasis 14: 19-26
127. Keenan R. M., Miller W. H., Lago M. A., Ali F. E., Bondinell W. E., Callahan J. F. et al. (1998) Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists. Bioorg. Med. Chem. Lett. 8: 3165-3170
128. Pluijm G. van der, Vloedgraven H. J., Ivanov B., Robey F. A., Grzesik W. J., Robey P. G. et al. (1996) Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res. 56: 1948-1955
129. Tran T. A., Mattern R. H., Zhu Q. and Goodman M. (1997) A novel RGD containing dodecapeptidomimetic which exhibits selective binding to the α vβ3 receptor. M. Bioorg. Med. Chem. Lett. 7: 997-1002
130. Burgess K., Lim D. and Mousa S. A. (1996) Synthesis and solution conformation of cyclo[RGDRGD]: a cyclic peptide with selectivity for the alpha v beta 3 receptor. J. Med. Chem. 39: 4520-4526
131. Peishoff C. E., Ali F. E., Bean J. W., Calvo R., D'Ambrosio C. A., Eggleston D. S. et al. (1992) Investigation of conformational specificity at GPIIb/IIIa: evaluation of conformationally constrained RGD peptides. J. Med. Chem. 35: 3962-3969
132. Mueller G., Gurrath M., Kessler H. and Timpl R. (1992) Dynamic forcing, a method for evaluating activity and selectivity profiles of RGD (Arg-Gly-Asp) peptides. Angew. Chem. Int. Ed. Engl. 31: 326